MESALAMINE | A207873 | TEVA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Warner Chilcott (US), LLC et al v. Teva Pharmaceuticals USA, Inc. et al 1 patentANDA 207873mesalamine delayed release capsules | E.D. Tex. | 2015-08-28 | Terminated 2019-03-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$2.35
per ea
Lowest NADAC/Unit
$2.35
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 60687055632MESALAMINE DR 400 MG CAPSULE | $2.35 | EA | Generic | — | 2026-06-17 |
| 00093590786MESALAMINE DR 400 MG CAPSULE | $2.35 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.